The current standard of therapy for CML is inactive against quiescent CML stem/progenitor cells [2–6], which make up a small fraction of the CD34+ cell population that is responsible for disease recurrence upon drug discontinuation [7–9]. Here, CD34 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.